Inogen Inc (NASDAQ:INGN) CFO Alison Bauerlein sold 5,000 shares of the company’s stock in a transaction dated Monday, June 11th. The shares were sold at an average price of $180.69, for a total transaction of $903,450.00. Following the sale, the chief financial officer now directly owns 9,161 shares of the company’s stock, valued at approximately $1,655,301.09. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Inogen traded up $0.90, hitting $185.53, during midday trading on Thursday, MarketBeat reports. The stock had a trading volume of 5,884 shares, compared to its average volume of 182,397. The firm has a market capitalization of $3.85 billion, a price-to-earnings ratio of 142.27, a P/E/G ratio of 4.57 and a beta of 1.10. Inogen Inc has a 52-week low of $89.01 and a 52-week high of $193.14.
Inogen (NASDAQ:INGN) last released its earnings results on Monday, April 30th. The medical technology company reported $0.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.19. The company had revenue of $79.05 million during the quarter, compared to analyst estimates of $63.86 million. Inogen had a net margin of 9.36% and a return on equity of 14.81%. The firm’s quarterly revenue was up 50.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.27 EPS. analysts predict that Inogen Inc will post 1.77 EPS for the current fiscal year.
Several equities research analysts have recently commented on the stock. ValuEngine raised shares of Inogen from a “hold” rating to a “buy” rating in a research report on Friday, April 6th. Leerink Swann reaffirmed an “outperform” rating and set a $170.00 price target (up previously from $150.00) on shares of Inogen in a research report on Tuesday, May 1st. BidaskClub raised shares of Inogen from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 6th. Zacks Investment Research lowered shares of Inogen from a “strong-buy” rating to a “hold” rating in a report on Monday, March 5th. Finally, Piper Jaffray Companies raised shares of Inogen from a “neutral” rating to an “overweight” rating in a report on Tuesday, February 20th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $178.00.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.